Microbiome Collaboration and Licensing Deals 2016-2025

Microbiome Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse microbiome collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in microbiome dealmaking
2.1. Introduction
2.2. Microbiome deals over the years
2.3. Most active microbiome dealmakers
2.4. Microbiome deals by deal type
2.5. Microbiome deals by therapy area
2.6. Microbiome deals by industry sector
2.7. Deal terms for microbiome deals
2.7.1 Microbiome deals headline values
2.7.2 Microbiome deal upfront payments
2.7.3 Microbiome deal milestone payments
2.7.4 Microbiome royalty rates

Chapter 3 – Leading microbiome deals
3.1. Introduction
3.2. Top microbiome deals by value

Chapter 4 – Most active microbiome dealmakers
4.1. Introduction
4.2. Most active microbiome dealmakers
4.3. Most active microbiome deals company profiles

Chapter 5 – Microbiome contracts dealmaking directory
5.1. Introduction
5.2. Microbiome contracts dealmaking directory

Chapter 6 – Microbiome dealmaking by technology type

Deal directory

Deal directory – Microbiome deals by company A-Z
Deal directory – Microbiome deals by deal type
Deal directory – Microbiome deals by therapy area

Deal type definitions

About Biopharma Research Ltd    
Current Partnering
Current Agreements
Recent report titles from Current Partnering

 
Table of figures

Figure 1: Microbiome deals since 2016
Figure 2: Active microbiome dealmaking activity – 2016 - 2025
Figure 3: Microbiome deals by deal type since 2016
Figure 4: Microbiome deals by therapy area since 2016
Figure 5: Microbiome deals by industry sector since 2016
Figure 6: Microbiome deals with a headline value
Figure 7: Microbiome deals with an upfront value
Figure 8: Microbiome deals with a milestone value
Figure 9: Microbiome deals with a royalty rate value
Figure 10: Top microbiome deals by value since 2016
Figure 11: Most active microbiome dealmakers 2016 - 2025
Figure 12: Microbiome deals by technology type since 2016

Pricing options

• $3,995: single-user (encrypted file - one user/device)
• $5,995: multi-user (encrypted file - up to 5 users/devices)
• $7,995: company (unencrypted PDF)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

Our guarantee

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

9 Meters Biopharma, Aarhus University, Abbvie, ADL Bionatur Solutions, ADM, AiCuris, Allergan, ALS Association, Amag Pharmaceuticals, American Skin Association, American Type Culture Collection (ATCC), AnimalBiome, AntibioTx, Arc Bio, Archer Daniels Midland Company, Arena Pharmaceuticals, Argonne National Laboratory, Arranta Bio, Artizan Biosciences, Assembly Biosciences, AstraZeneca, Aurealis Therapeutics, Azitra, Bacthera, BASF, Bayer, Bayer CropScience, Baylor College of Medicine, Baylor Miraca Genetics Laboratories, BCD Bioscience, Beam Therapeutics, Bertin Pharma, Bill and Melinda Gates Foundation, Bio-Me, Bio-Rad Laboratories, BIOASTER, Biocodex Microbiota Foundation, Biocogent, Biofortis, Biohaven Pharmaceuticals, BIOHM Health Inc, BiomeBank, Biomedical Advanced Research and Development Authority, Biomica, Biomillenia, Biomodels, BiomX, BionX Medical Technologies, Bio Palette, Biosortia Pharmaceuticals, bitBiome, Bloom Science, Boehringer Ingelheim, Boston University School of Medicine, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Brown University, Cancer Research UK, CARB-X, Carbiotix, Cargill, Cedars-Sinai Medical Center, Children's Hospital Boston, Circuit Clinical, Clalit Health Services, CN Bio, Columbia University, Columbia University Medical Center, Commense, Compass Minerals Plant Nutrition, ConsortiaTX, COPD Foundation, CoreBiome, Cornell University, Corteva Agriscience, CosmosID, Crohn's and Colitis Foundation of America, CSIR - Institute of Microbial Technology, Dana-Farber Cancer Institute, DayTwo, Debiopharm, Defense Advanced Research Projects Agency, Dermala, Diversigen, DuPont, DuPont Pharmaceuticals, DuPont Pioneer, Eagle Genomics, EcoMetrix, Elanco, Eligo Bioscience, Emory University, Emulate, Enterome Bioscience, Euformatics, European Commission, Evah, Evelo Biosciences, Evogene, Evolve BioSystems, Evvy, Exacta Bioscience, Federation Bio, Felix Biotechnology, Ferring Pharmaceuticals, Finch Therapeutics, Florida International University, Food Marble Digestive Health, Forsyth Institute, Fred Hutchinson Cancer Research Center, French National Institute for Agricultural Research, Fundacion Progreso y Salud, Galmed Pharmaceuticals, Genentech, General Automation Lab Technologies, Genetic Analysis, Genome and Company, Gilead Sciences, Ginkgo BioWorks, Glycosyn, Gnubiotics Sciences, GSK, Gusto Global, Hackensack Meridian Health, Hadassah Medical Center, Harvard Medical School, Harvard T.H. Chan School of Public Health, Harvard University, Helomics, Holobiome, Horizon Europe, Hudson Institute of Medical Research, IBM, iGenomix, Illumina, Innovate Biopharmaceuticals, Inserm, Inspirotec, Institut Gustave Roussy, Institut National Recherche Agronomique, International Centre for Diarrhoeal Disease Research, Intract Pharma, Intralytix, ISOThrive, Jackson Laboratory, Janssen Human Microbiome Institute, Janssen Research & Development, Janssen Therapeutics, Jennewein Biotechnologie, Johns Hopkins University, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, JSR, Juntendo University, Kaleido Biosciences, Kallyope, Kantonsspital St. Gallen, Kanvas Biosciences, Karolinska Institute, Keio Gijuku University, King's College Hospital, Kings College London, L'Oreal, Latham BioPharm Group, Lavie Bio, Lawrence Livermore National Laboratory, Leiden University, Leidos, LNC, Locus Biosciences, Loreal, Lupus Research Alliance, Lurie Children's Hospital of Chicago, Lysando, MaaT Pharma, Mainz Biomed, Marrone Bio Innovations, Mars Petcare, Maruho, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Mawi DNA Technologies, Mayo Clinic, McGill University, MD Anderson Cancer Center, Medical College of Wisconsin, Medical University of Graz, Melanoma Research Alliance, Memorial Sloan Kettering Cancer Center, Merck KGaA, Metabiomics, MetaboGen, Micreos, Microba Life Sciences, MicroBiome Therapeutics, Microbiome Therapeutics Innovation Group, Microbiotica, MicroGenDX, Micronoma, Microsoft, Microviable Therapeutics, MilliporeSigma, Monsanto, Moss Genomics, MRM Health, MSD, MyBiotics Pharma, National Cancer Center of Japan, National Eczema Association, National Institute of Arthritis and Musculoskeletal Diseases, National Institutes of Health, National Organization for Rare Disorders, National Psoriasis Foundation, Nestle Health Science, Nexilico, Northeastern University, Northwestern University, North Zealand University Hospital, Norwegian University of Science, Novome Biotechnologies, NuBiyota, Nutricion, Nutrilinea, NYU Langone Medical Center, Oklahoma Medical Research Foundation, Oncology Venture, One Codex, OpenBiome, Opentrons Labworks, OptiBiotix, Osel, Oslo University Hospital, Pancreatic Cancer Collective, Pathogen and Microbiome Institute, Penn State Microbiome Center, Pennsylvania State University, Persephone Biosciences, Pfizer, PharmaBiome, Pharmabiota, Pharmatest Services, Plan France Relance, Pragma Bio, Precision Biomonitoring, Prescient Medical, Proteic Bioscience, Puma Biotechnology, Purdue Research Foundation, Purdue University, PureTech Health, QIAGEN, Quadram Institute, Quark Venture, Rebiotix, Research Council of Norway, Resilient Biotics, RIKEN Research Institute, Ritter Pharmaceuticals, Roquette, Roswell Park Cancer Institute, Rutgers University, SACCO, SATT Lutech, Second Genome, Sequential Skin, Seres Therapeutics, Servatus Biopharmaceuticals, Sheba Medical Center, Siolta Therapeutics, Sirenas, SKAN Research Trust, Skive Hospital, Solarea Bio, Sonic Healthcare, Spanish National Cancer Research Centre, Stanford Cancer Institute, Stanford University School of Medicine, Statens Serum Institute, Sun Genomics, Swiss Integrative Center for Human Health, Synlogic, Synthetic Biologics, Taconic Biosciences, Takeda Pharmaceutical, Tata Chemicals, Tel Aviv University, Texas Children’s Hospital, The BioCollective, The Healthy Aging Company, The Parker Institute For Cancer Immunotherapy, Thermo Fisher Scientific, Tokyo Medical and Dental University, Transnetyx, Tsinghua University, uBiome, Unilever, UNION Therapeutics, Universite catholique de Louvain, University Medical Center Utrecht, University of Adelaide, University of Alberta, University of British Columbia, University of Buffalo, University of California, San Diego, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Chicago, University of Cincinnati, University of Heidelberg, University of Houston, University of Illinois, University of Lausanne, University of Manchester, University of Maryland School of Medicine, University of Massachusetts Medical School, University of Miami, University of Michigan, University of Minnesota, University of Nebraska, University of New South Wales, University of Oslo, University of Pennsylvania, University of Pittsburgh, University of Queensland, University of Rhode Island, University of Sheffield, University of South Alabama (USA) Mitchell Cancer Institute, University of South Carolina, University of Texas, University of Verona, University of Virginia, University of Washington, University Paris Diderot, Valbiotis, Vanderbilt University, Vedanta Biosciences, Verb Biotics, Vertex Pharmaceuticals, ViennaLab Diagnostics, Viome, Virginia Catalyst, Virginia Commonwealth University, Virginia Tech, Washington University in St Louis, Weizmann Institute, Xbiome, Xycrobe Therapeutics, Yale School of Medicine, Yale University, Yeda Research and Development Company, Yili Industrial Group, Zymo Research

About Current Partnering

A definitive, evidence-based approach to dealmaking intelligence

Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.

Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.

All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.

Our methodology

Built on a continuously updated proprietary database

All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.

Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.

Comprehensive and verifiable data sourcing

Deal data is sourced from publicly available industry disclosures, including:

• Company press releases and announcements
• SEC filings and equivalent regulatory disclosures
• Company and investor presentations
• Conference materials and company websites

All sources are captured and referenced, enabling full transparency and user verification.

Broad coverage across deal types and structures

Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:

• Licensing and co-development
• Research and collaborative R&D
• Manufacturing, supply, and distribution
• Commercialisation and co-promotion
• Equity investments, joint ventures, and asset transactions
• Options, royalties, and financing agreements

This breadth ensures a complete view of how partnerships are structured across the life sciences sector.

Structured, standardised analysis

Every deal is analysed using a consistent framework, capturing (where disclosed):

• Financial terms — including upfront payments, milestones, and royalties
• Rights allocation — development, manufacturing, and commercialization responsibilities
• Deal structure — exclusivity, territorial scope, and agreement type
• Contractual provisions — clauses defining risk, control, and value-sharing

Each deal record is fully categorised, including data fields such as:

• Therapy area and technology type
• Stage of development
• Asset type and deal components
• Geographic scope and exclusivity
• Source documentation, including press releases and SEC filings

Financial normalisation for comparability

All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.

Contract-level insight

Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.

This enables users to understand:

• How financial mechanisms are defined and triggered
• How responsibilities are operationalised between parties
• How flexibility, risk, and control are allocated within agreements

Designed for real-world application

Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:

• Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
• Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
• Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight

Common use cases include:

• Benchmarking comparable transactions
• Supporting valuation and deal structuring
• Preparing for negotiations
• Evaluating potential partners
• Informing internal strategy with real-world evidence

A trusted industry reference

With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.

By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.